JARID2, another downstream target of miR-155, has been shown to suppress the expression of Est-1, a negative modulator of Th17 cells in DSS-induced colitis, and promote the expression of IL-6, IL-17, and IL-23, as well as the maturation of Th17 cells [80,81]. Here, IL6 is linked to colitis.